Glenn E Palomaki1, Bhanu Kalra2, Tanya Kumar2, Amita S Patel2, Gopal Savjani2, Laura C Torchen3, Andrea Dunaif4, Anthony Morrison2, Geralyn M Lambert-Messerlian5, Ajay Kumar2. 1. Department of Pathology and Laboratory Medicine, Women & Infants Hospital and the Alpert Medical School at Brown University, Providence, Rhode Island; Savjani Institute for Health Research, Windham, Maine. Electronic address: gpalomaki@ipmms.org. 2. Ansh Labs, Webster, Texas. 3. Division of Endocrinology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 4. Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University, Chicago, Illinois. 5. Department of Pathology and Laboratory Medicine, Women & Infants Hospital and the Alpert Medical School at Brown University, Providence, Rhode Island; Department of Obstetrics and Gynecology, Women and Infants Hospital, Providence, Rhode Island.
Abstract
OBJECTIVE: To examine whether accounting for a woman's age and body mass index (BMI) would improve the ability of antimüllerian hormone (AMH) to distinguish between women with (cases) and without (controls) polycystic ovarian syndrome (PCOS). DESIGN: An opportunistic case-control dataset of reproductive age women having evaluations for PCOS as defined by National Institutes of Health criteria. SETTING: Two medical centers in the United States enrolled women. Serum samples were analyzed for relevant analytes. PATIENTS: Women were between 18 and 39 years of age when samples and clinical information were collected. Residual samples had been stored for 2-17 years. AMH was measured via immunoassay. INTERVENTIONS: None; this was an observational study. MAIN OUTCOME MEASURES: Detection and false-positive rates for PCOS were computed for AMH results expressed as multiples of the median (MoM) both before and after adjustment for the woman's age and BMI. RESULTS: Using unadjusted AMH MoM results, 168 cases (78%) cases were at or beyond the 90th centile of controls (2.47 MoM). After accounting for each woman's age and BMI, 188 (87%) of those women were beyond the 90th centile of controls (2.20 MoM), a significant increase (P = .015). The adjusted AMH MoM levels fitted logarithmic normal distributions well (mean, standard deviation for controls and cases of 0.0000, 0.2765 and 0.6884, 0.2874, respectively) and this allowed for computation of patient-specific PCOS risks. CONCLUSIONS: Accounting for the woman's age and BMI resulted in significantly higher AMH-based detection rates for PCOS at a 10% false-positive rate, and patient-specific PCOS risks could be computed.
OBJECTIVE: To examine whether accounting for a woman's age and body mass index (BMI) would improve the ability of antimüllerian hormone (AMH) to distinguish between women with (cases) and without (controls) polycystic ovarian syndrome (PCOS). DESIGN: An opportunistic case-control dataset of reproductive agewomen having evaluations for PCOS as defined by National Institutes of Health criteria. SETTING: Two medical centers in the United States enrolled women. Serum samples were analyzed for relevant analytes. PATIENTS: Women were between 18 and 39 years of age when samples and clinical information were collected. Residual samples had been stored for 2-17 years. AMH was measured via immunoassay. INTERVENTIONS: None; this was an observational study. MAIN OUTCOME MEASURES: Detection and false-positive rates for PCOS were computed for AMH results expressed as multiples of the median (MoM) both before and after adjustment for the woman's age and BMI. RESULTS: Using unadjusted AMHMoM results, 168 cases (78%) cases were at or beyond the 90th centile of controls (2.47 MoM). After accounting for each woman's age and BMI, 188 (87%) of those women were beyond the 90th centile of controls (2.20 MoM), a significant increase (P = .015). The adjusted AMHMoM levels fitted logarithmic normal distributions well (mean, standard deviation for controls and cases of 0.0000, 0.2765 and 0.6884, 0.2874, respectively) and this allowed for computation of patient-specific PCOS risks. CONCLUSIONS: Accounting for the woman's age and BMI resulted in significantly higher AMH-based detection rates for PCOS at a 10% false-positive rate, and patient-specific PCOS risks could be computed.
Authors: M P Lauritsen; J G Bentzen; A Pinborg; A Loft; J L Forman; L L Thuesen; A Cohen; D M Hougaard; A Nyboe Andersen Journal: Hum Reprod Date: 2014-01-16 Impact factor: 6.918
Authors: R B Pepinsky; L K Sinclair; E P Chow; R J Mattaliano; T F Manganaro; P K Donahoe; R L Cate Journal: J Biol Chem Date: 1988-12-15 Impact factor: 5.157
Authors: Sudha K Yalamanchi; Susan Sam; Maria O Cardenas; Louisa W Holaday; Margrit Urbanek; Andrea Dunaif Journal: Obesity (Silver Spring) Date: 2012-02-02 Impact factor: 5.002
Authors: Wendy M Wolf; Rachel A Wattick; Olivia N Kinkade; Melissa D Olfert Journal: Int J Environ Res Public Health Date: 2018-11-20 Impact factor: 3.390
Authors: Helena J Teede; Marie L Misso; Michael F Costello; Anuja Dokras; Joop Laven; Lisa Moran; Terhi Piltonen; Robert J Norman Journal: Clin Endocrinol (Oxf) Date: 2018-07-19 Impact factor: 3.478
Authors: Ashley M Eskew; Bronwyn S Bedrick; Jorge E Chavarro; Joan K Riley; Emily S Jungheim Journal: Reprod Biol Endocrinol Date: 2022-02-19 Impact factor: 5.211